Vertex to present phase 3 data highlighting suzetrigine's potential as a first-in-class, highly selective pain signal inhibitor at the american society of anesthesiologists annual meeting

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that the company will present its pivotal phase 3 data on suzetrigine, an investigational, oral, highly selective nav1.8 pain signal inhibitor for the treatment of moderate-to-severe acute pain, at the annual meeting of the american society of anesthesiologists (asa), taking place from october 18-22, 2024 in philadelphia, pennsylvania. abstract a1187 — “randomized, placebo-controlled, phase 3 trials of s.
VRTX Ratings Summary
VRTX Quant Ranking